Therapeutic Prospective of a Spore-Forming Probiotic—Bacillus clausii UBBC07 Against Acetaminophen-Induced Uremia in Rats
- 11 Downloads
To screen Bacillus clausii UBBC07 as a putative probiotic strain and to examine the protective effect of probiotic—B. clausii UBBC07 spore on uremia on rats induced by acetaminophen. In vitro tests performed to screen potential probiotic strains were gastric and bile acid resistance and ability to reduce pathogen adhesion to surfaces. An in vivo study was performed on rats (n = 18) which were randomly divided into three groups: group I, control—receives normal food and water, groups II and III receive acetaminophen i.p. at the dose of 550 mg/kg/day for 10 days, groups III was treated with B. clausii UBBC07 at a dose of 1 × 109 CFU/day for 15 days. Urea, creatinine, malondialdehyde (MDA), and GSH levels and antioxidant enzymes like super oxide dismutase (SOD) and catalase activity were considered to analyze renal failure. Plasma urea and creatinine levels (p < 0.05) significantly increase and SOD, catalase, and GSH activity level significantly decrease in group II as compared with the control group. After treatment with probiotic, there was a significant increase in SOD and catalase (p < 0.05) and a significant decrease in serum urea, creatinine, and MDA (p < 0.05) in group III in response to group II. The results also revealed that probiotic was able to tolerate pH 3.0–9.0 and 0.3% bile salt. The present study suggests that B. clausii UBBC07 could be used as a novel alternative natural therapy for uremia, a major syndrome of CKD.
KeywordsProbiotic Uremia Nephrotoxicity Bacillus clausii
The authors gratefully acknowledge Unique Biotech Limited, Unit-II, Hyderabad, India for supplying probiotic strains of Bacillus clausii.
Compliance with Ethical Standards
Institutional Animal Ethics Committee approved the experimental protocol SSR/IAEC/2018/08.The handling of the laboratory animals was performed according to CPCSEA guideline, India.
Conflict of Interest
The authors declare that they have no conflict of interest.
- 3.Moore M, Thor H, Moore G, Nelson S, Moldéus P, Orrenius S (1985) The toxicity of acetaminophen and N-acetyl-p-benzoquinone imine in isolated hepatocytes is associated with thiol depletion and increased cytosolic Ca2+. J Biol Chem 260:13035–13040. http://www.jbc.org/content/260/24/13035.long Google Scholar
- 14.Urdaci MC, Bressollier P, Pinchuk I (2004) Bacillus clausii probiotic strains antimicrobial and immunomodulatory activities. J Clin Gastroenterol 38:S86–S90. https://doi.org/10.1097/01.mcg.0000128925.06662.69 CrossRefGoogle Scholar
- 17.Marklund S, Marklund G (1974) Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 47:469–474. https://doi.org/10.1111/j.1432-1033.1974.tb03714.x CrossRefGoogle Scholar
- 23.Bouhafs L, Moudilou EN, Exbrayat JM, Lahouel M, Idoui T (2015) Protective effects of probiotic Lactobacillus plantarum BJ0021 on liver and kidney oxidative stress and apoptosis induced by endosulfan in pregnant rats. Ren Fail 37:1370–1378. https://doi.org/10.3109/0886022X.2015.1073543 CrossRefGoogle Scholar
- 24.Sall M, Dou L, Cerini C, Poitevin S, Brunet P, Burtey S (2014) The aryl hydrocarbon receptor-activating effect of uremic toxins from tryptophan metabolism: a new concept to understand cardiovascular complications of chronic kidney disease. Toxins 6:934–949. https://doi.org/10.3390/toxins6030934 CrossRefGoogle Scholar
- 27.Wong J, Piceno YM, DeSantis TZ, Pahl M, Andersen GL, Vaziri ND (2014) Expansion of urease and uricase-containing, indole- and p-cresol-forming and contraction of short chain fatty acid-producing intestinal bacteria in ESRD. Am J Nephrol 39:230–237. https://doi.org/10.1159/000360010 CrossRefGoogle Scholar
- 28.Hida M, Aiba Y, Sawamura S, Satoh T, Koga Y (1996) Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron 74:349–355. https://doi.org/10.1159/000189334 CrossRefGoogle Scholar
- 30.Ranganathan N, Patel BG, Ranganathan P, Marczely J, Dheer R, Pechenyak B, Dunn SR, Verstraete W, Decroos K, Mehta R, Friedman EA (2006) In vitro and in vivo assessment of intraintestinal bacteriotherapy in chronic kidney disease. ASAIO J 52:70–79. https://doi.org/10.1097/01.mat.0000191345.45735.00 CrossRefGoogle Scholar
- 31.Ranganathan N, Ranganathan P, Friedman EA, Joseph A, Delano B, Goldfarb DS, Tam P, Rao AV, Anteyi E, Musso CG (2010) Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease. Adv Ther 27:634–647. https://doi.org/10.1007/s12325-010-0059-9 CrossRefGoogle Scholar
- 33.Natarajan R, Pechenyak B, Vyas U, Ranganathan P, Weinberg A, Liang P, Mallappallil MC, Norin AJ, Friedman EA, Saggi SJ (2014) Randomized controlled trial of strain-specific probiotic formulation (Renadyl) in dialysis patients. Biomed Res Int 2014:568–571. https://doi.org/10.1155/2014/568571 Google Scholar
- 35.Simenhoff ML, Dunn SR, Zollner GP, Fitzpatrick ME, Emery SM, Sandine WE, Ayres JW (1996) Biomodulation of the toxic and nutritional effects of small bowel bacterial overgrowth in end-stage kidney disease using freeze-dried Lactobacillus acidophilus. Miner Electrolyte Metab 22:92–96Google Scholar
- 36.Dunn SR, Simenhoff ML, Ahmed KE, Gaughan WJ, Eltayeb BO, Fitzpatrick ME, Emery SM, Ayres JW, Holt KE (1998) Effect of oral administration of freeze-dried Lactobacillus acidophilus on small bowel bacterial overgrowth in patients with end stage kidney disease: reducing uremic toxins and improving nutrition. Int Dairy J 8:545–553. https://doi.org/10.1016/S0958-6946(98)00081-8 CrossRefGoogle Scholar